Inhalation Sciences' PreciseInhale delivers exceptional precision in ground-breaking inhalable nicotine study
September 24, Stockholm, Sweden. In a ground-breaking publication on inhalable nicotine PreciseInhale aerosol technology revealed new data on the drug’s pharmacokinetic behavior that until now was unobtainable. ISAB CEO Manoush Masarrat: “The strategic value of data of this precision is immense. It enables drug developers to establish a failsafe strategy for their inhaled medications from day one.”The preclinical study, by Philip Morris International, analyzed and measured the Pharmacokinetics of two formulations of dry powder nicotine intended for inhalation delivery. As a water-soluble